

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Tralokinumab for treating moderate to severe atopic dermatitis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

There were no equality issues raised during the scoping process. However, in a previous appraisal for this indication the committee noted that it is possible that the assessment tools for assessing the severity of atopic dermatitis and the response to treatment may not be sensitive enough in people with some skin colours.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee should take into account skin colour and how this could affect the assessment of the severity of atopic dermatitis and response to treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No. The scope already states that different skin colour subgroups should be considered if evidence allows.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 4/02/2021